GLSI

Greenwich Lifesciences Inc

Add to Watchlist

Advanced Chart

11.570

+0.08(0.696%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

11.740

Open

11.490

VWAP

11.51

Vol

37.27K

Mkt Cap

154.67M

Low

11.160

Amount

429.17K

EV/EBITDA(TTM)

Total Shares

12.88M

150.85M

EV/OCF(TTM)

P/S(TTM)

Greenwich LifeSciences, Inc. is a clinical-stage biopharmaceutical company focused on the development of GP2, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery. GP2 is a 9-amino acid transmembrane peptide of the human epidermal growth factor receptor 2 (HER2) /neu protein, a cell surface receptor protein that is expressed in a variety of common cancers. It has commenced a Phase III clinical trial, Flamingo-01, an immunotherapy to prevent breast cancer recurrences. GP2 is delivered in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF) to induce GP2 peptide-specific immunity. GP2 treatment is administered via an intradermal injection by mixing GP2 peptide and GM-CSF at the time of administration. Its cancer immunotherapy seeks to stimulate an individual's immune system to selectively attack cancer cells while not affecting normal cells or to deliver immune system components to inhibit the spread of cancer.

1 Analyst Rating

237.08% Upside

Wall Street analysts forecast GLSI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GLSI is 39.00 USD with a low forecast of 39.00 USD and a high forecast of 39.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

237.08% Upside

Current: 11.570

Low

39.00

Averages

39.00

High

39.00

237.08% Upside

Current: 11.570

Low

39.00

Averages

39.00

High

39.00

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$38 → $39

2025-04-21

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$38 → $39

2025-04-21

Maintains

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Reiterates

$38

2025-02-11

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$38

2025-02-11

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Yi Chen

Strong Buy

Maintains

$36 → $38

2024-08-23

Reason

HC Wainwright & Co.

Yi Chen

Price Target

$36 → $38

2024-08-23

Maintains

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Greenwich Lifesciences Inc (GLSI.O) is -12.22, compared to its 5-year average forward P/E of -30.45. For a more detailed relative valuation and DCF analysis to assess Greenwich Lifesciences Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-30.45

Current PE

-12.22

Overvalued PE

3.40

Undervalued PE

-64.31

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00